menu

Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

4 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Do you know how to best utilize immunotherapy and antibody-drug conjugates to improve treatment outcomes in your patients with metastatic urothelial cancer? Listen in as Drs. Mamta Parikh and Daniel Petrylak break down the data surrounding these therapies so you can improve the care you provide.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mamta Parikh, MD, MS
    Assistant Professor, Division of Hematology and Oncology
    UC Davis Comprehensive Cancer Center
    Sacramento, CA

    Consulting Fees: AstraZeneca, Exelixis, Oncocyte, Seagen Inc.
    Research Funding: Karyopharm

    Faculty:
    Daniel P. Petrylak, MD
    Professor of Medicine and Urology
    Chief, Genitourinary Oncology
    Yale Cancer Center
    New Haven, CT

    Consulting Fees and or Advisory and Speaker: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen
    Research Funding: Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics
    Stock Ownership: Bellicum, Tyme

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate immune-oncologic therapies for patients with mUC based on the NCCN Clinical Practice Guideline recommendations
    • Apply strategies for the optimal management of adverse events related to antibody-drug conjugates
    • Explain how emerging adjuvant and neoadjuvant immunotherapy strategies may transform the treatment paradigm for mUC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with genitourinary cancers globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Expert Interview activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until January 5, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-066-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Exelixis, Merck, and Seagen Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Do you know how to best utilize immunotherapy and antibody-drug conjugates to improve treatment outcomes in your patients with metastatic urothelial cancer? Listen in as Drs. Mamta Parikh and Daniel Petrylak break down the data surrounding these therapies so you can improve the care you provide.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mamta Parikh, MD, MS
    Assistant Professor, Division of Hematology and Oncology
    UC Davis Comprehensive Cancer Center
    Sacramento, CA

    Consulting Fees: AstraZeneca, Exelixis, Oncocyte, Seagen Inc.
    Research Funding: Karyopharm

    Faculty:
    Daniel P. Petrylak, MD
    Professor of Medicine and Urology
    Chief, Genitourinary Oncology
    Yale Cancer Center
    New Haven, CT

    Consulting Fees and or Advisory and Speaker: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen
    Research Funding: Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics
    Stock Ownership: Bellicum, Tyme

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate immune-oncologic therapies for patients with mUC based on the NCCN Clinical Practice Guideline recommendations
    • Apply strategies for the optimal management of adverse events related to antibody-drug conjugates
    • Explain how emerging adjuvant and neoadjuvant immunotherapy strategies may transform the treatment paradigm for mUC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with genitourinary cancers globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Expert Interview activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until January 5, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of Pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-22-066-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Exelixis, Merck, and Seagen Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule8 Feb 2023